153 related articles for article (PubMed ID: 38017341)
1. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
[TBL] [Abstract][Full Text] [Related]
2. Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer.
Shibutani Y; Tajiri K; Suzuki S; Enokida T; Sagara A; Okano S; Fujisawa T; Sato F; Yumoto T; Sano M; Kawasaki T; Tahara M
Cancer Med; 2023 Nov; 12(22):20773-20782. PubMed ID: 37902136
[TBL] [Abstract][Full Text] [Related]
3. Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Reed N; Glen H; Gerrard G; Good J; Lei M; Lyon AR; Strachan M; Wadsley J; Newbold K
Clin Oncol (R Coll Radiol); 2020 May; 32(5):e145-e153. PubMed ID: 31843241
[TBL] [Abstract][Full Text] [Related]
4. Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting.
De Leo S; Trevisan M; Colombo C; Moneta C; Giancola N; Fugazzola L
Thyroid; 2023 Jan; 33(1):74-81. PubMed ID: 36326203
[No Abstract] [Full Text] [Related]
5. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study.
Ionescu DD;
Clin Drug Investig; 2009; 29(12):767-76. PubMed ID: 19888783
[TBL] [Abstract][Full Text] [Related]
7. Impact of a pill box clinic to improve systolic blood pressure in veterans with uncontrolled hypertension taking 3 or more antihypertensive medications.
Porter AK; Taylor SR; Yabut AH; Al-Achi A
J Manag Care Spec Pharm; 2014 Sep; 20(9):905-11. PubMed ID: 25166289
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data.
Otani Y; Kasai H; Tanigawara Y
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):188-198. PubMed ID: 33471960
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.
Germino FW; Neutel JM; Dubiel R; Maa JF; Chavanu KJ
Am J Cardiovasc Drugs; 2012 Oct; 12(5):325-33. PubMed ID: 22920048
[TBL] [Abstract][Full Text] [Related]
10. Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer.
Jimenez-Fonseca P
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):17-25. PubMed ID: 36202605
[TBL] [Abstract][Full Text] [Related]
11. Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm.
Colombo C; Ceruti D; De Leo S; Bilo G; Trevisan M; Giancola N; Moneta C; Parati G; Persani L; Fugazzola L
Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37097040
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.
Chrysant SG
Clin Drug Investig; 2010; 30(7):473-82. PubMed ID: 20528002
[TBL] [Abstract][Full Text] [Related]
13. Factors involved in early lenvatinib dose reduction: a retrospective analysis.
Suyama K; Tomiguchi M; Takeshita T; Sueta A; Yamamoto-Ibusuki M; Shimokawa M; Yamamoto Y; Iwase H
Med Oncol; 2018 Jan; 35(3):19. PubMed ID: 29387983
[TBL] [Abstract][Full Text] [Related]
14. [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
Chazova IE; Martynyuk TV
Ter Arkh; 2013; 85(9):35-45. PubMed ID: 24261228
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of long-acting nifedipine GITS/OROS monotherapy or combination therapy in hypertensive patients: results of a 12-week international, prospective, multicentre, observational study.
Ueng KC; Ningling S; El Maksod A; Hung KY; Yuehui Y
Clin Drug Investig; 2011; 31(9):631-42. PubMed ID: 21591818
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.
Sierra A; Roca-Cusachs A; Redón J; Marín R; Luque M; Figuera M; Garcia-Garcia M; Falkon L
Clin Drug Investig; 2009; 29(7):459-469. PubMed ID: 19499963
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy.
Punzi H; Shojaee A; Maa JF;
Ther Adv Cardiovasc Dis; 2012 Aug; 6(4):149-61. PubMed ID: 22855062
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes Remission Clinical Trial (DiRECT).
Leslie WS; Ali E; Harris L; Messow CM; Brosnahan NT; Thom G; McCombie EL; Barnes AC; Sattar N; Taylor R; Lean MEJ
Diabetologia; 2021 Sep; 64(9):1927-1938. PubMed ID: 34056684
[TBL] [Abstract][Full Text] [Related]
19. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.
Ogilvie RI; Anand S; Roy P; De Souza S;
Clin Drug Investig; 2008; 28(11):673-86. PubMed ID: 18840010
[TBL] [Abstract][Full Text] [Related]
20. Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication.
Neldam S; Edwards C
Expert Opin Pharmacother; 2009 Feb; 10(3):345-52. PubMed ID: 19191674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
